Statement by Congressman Pallone on the House Passage of the Food and Drug Administration Safety and Innovation Act
June 20, 2012
WASHINGTON DC – Congressman Frank Pallone, Jr. (NJ-06), Senior Democrat on the Energy & Commerce Health Subcommittee, released the following statement praising the passage of the Food and Drug Administration (FDA) Safety and Innovation Act, which represents an agreement of earlier House and Senate versions of the FDA user-fee reauthorizations:
“I applaud the House passage of the FDA Safety and Innovation Act, a bipartisan bill that will ensure that Americans have access to safe and effective new medicines and medical devices. It will also reduce drug costs for consumers by speeding the approval of lower-cost generic drugs, as well as enhance FDA’s ability to police an ever-growing global supply chain to improve patient safety.
“The bill is a product of bipartisan collaboration and compromise. It is good for the FDA, industry and patients, and will reduce federal spending by $311 million over the next ten years. I look forward to the final version passing the Senate and President Obama signing it into law.”